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Abstract 
Background: Adaptive servo-ventilation (ASV) is used to treat heart failure (HF). 
However, it is unclear whether ASV improves the long-term prognosis for all patients with 
HF, regardless of the severity of sleep-disordered breathing (SDB). We therefore aimed to 
estimate the long-term prognosis associated with ASV therapy for patients with HF by the 
severity of SDB. 
Methods: Sixty-one consecutive patients with HF (mean age ± standard deviation: 70 ± 10 
years) were initiated on ASV therapy for HF treatment after polysomnography. Patients 
were then classified into the following three groups based on their apnea–hypopnea index 
(AHI): a severe group with an AHI of ≥40/h (n = 28); a moderate group with an AHI of 
≥20/h but <40/h (n = 20); and a mild group with an AHI of <20/h (n = 13). To estimate 
long-term prognosis, we reviewed the 3-year follow-up data, including that concerning 
fatal cardiovascular events (death from myocardial infarction, cardioembolic stroke, and 
fatal cardiac arrhythmias).  
Results: No significant differences were observed between the three study groups in the 
risk of fatal cardiovascular events (p = 0.207). 
Conclusions: Our results suggest that ASV therapy is associated with a good prognosis 
and that ASV therapy is effective, regardless of the severity of SDB. 
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Abbreviations List 
AHI = apnea–hypopnea index 
ASV = adaptive servo-ventilation 
BNP = brain natriuretic peptide 
CSA = central sleep apnea 
CSR = Cheyne–Stokes respiration 
HF = heart failure 
LVEF = left ventricular ejection fraction 
ODI = oxygen desaturation index 
SDB = sleep-disordered breathing 
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Introduction 
 Sleep-disordered breathing (SDB) has a close relation to heart failure (HF), the 
incidence of fatal cardiovascular events, and mortality [1]. Adaptive servo-ventilation 
(ASV) therapy has been shown to be effective for central sleep apnea (CSA) and Cheyne–
Stokes respiration (CSR) [2,3]. Recently, ASV therapy has also been used to treat patients 
with HF who also have CSA and CSR [2,4,5] as well as patients with SDB, including those 
with obstructive sleep apnea [6,7]. Previously, we reported that ASV therapy for patients 
with mild SDB resulted in almost equal improvements in brain natriuretic peptide (BNP) 
and left ventricular ejection fraction (LVEF) compared with patients with moderate and 
severe SDB, thus demonstrating that ASV therapy was effective for all patients with HF 
[8]. However, previous reports have suggested that there is a negative relationship between 
the severity of SDB and prognosis [1,9]. It remained unclear as to whether ASV could 
improve the long-term prognosis of patients with HF, regardless of the severity of SDB. 
 We aimed to clarify whether ASV therapy improved the short- and long-term 
prognosis in patients with HF, regardless of the severity of SDB. We hypothesized that 
both the short- and long-term prognosis of patients with HF could be improved by 
improving their SDB. 
 
Methods 
Study design and ethical considerations 
 The present study was a single-center, prospective cohort study of HF patients 
that was conducted between April 2007 and April 2010 at Isesaki Municipal Hospital. This 
study was performed according to the ethical guidelines of the 1975 Declaration of 
Helsinki. The research protocol was approved by the Institutional Review Board for 
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Human Research of Isesaki Municipal Hospital, and all patients gave written consent to the 
study. 
We included 61 consecutive patients with HF who were initiated on ASV 
therapy after polysomnography to screen for SDB. All patients had a history of HF, such 
as, coronary artery disease, valvular disease, and cardiomyopathy, and were classified into 
class II–IV, according to the criteria of the New York Heart Association. 
All patients were treated with optimal medical therapy for HF before undergoing 
full-night polysomnography and were prescribed ASV therapy. For analysis, patients were 
classified into the following three groups based on the apnea–hypopnea index (AHI): a 
severe group with an AHI of ≥40/h (n = 28); a moderate group with an AHI of ≥20/h but 
<40/h (n = 20); and a mild group with an AHI of <20/h (n = 13). To estimate long-term 
prognosis, we reviewed the 3-year follow-up data, including that concerning fatal 
cardiovascular events (death from myocardial infarction, cardio-embolic stroke, and fatal 
cardiac arrhythmias). 
Sleep evaluation and treatment devices 
 We conducted full-night polysomnography to analyze SDB for all patients with 
HF, using a digital polygraph (P-Series Plus; Compumedics, Abbotsville, Australia) 
according to a commonly used method. We measured nasal airflow with an airflow 
pressure transducer, arterial oxygen saturation by pulse oximetry with a finger probe 
(Nonin 8000J Adult Flex Sensor), and chest and abdominal movement using two bands 
(inductive respiratory bands), an electroencephalogram, an electrooculogram, and a chin 
electromyogram. We scored sleep staging and arousal according to generally accepted 
definitions and methods [10-12]. 
 After confirmation of SDB and grading of severity by full-night 
polysomnography, we used an ASV device (AutoSet-CS; ResMed, Sydney, Australia) with 
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a full facemask (ResMed) for all HF patients. We set the expiratory positive airway 
pressure at 4 cm H2O and the inspiratory support pressure at 3–8 cm H2O. The backup 
respiratory rate for apnea or hypopnea was 15 breaths/min. We checked patient compliance 
with ASV therapy from the ASV device. If apnea or hypopnea was observed, the ASV 
device modified the expiratory positive airway pressure and inspiratory support to fit the 
patients’ breathing as necessary. 
Data collection 
 We defined underlying heart disease as ischemic cardiomyopathy, valvular heart 
disease, and cardiomyopathy. Patients with ischemic cardiomyopathy were defined as 
those with angina pectoris, unstable angina pectoris, or acute coronary syndrome by 
coronary angiography in the past. Patients with valvular heart disease were defined as 
those with uncontrolled refractory HF after surgery for valvular heart disease or those with 
HF induced by valvular heart disease but without an indication for surgery. Patients with 
cardiomyopathy were defined as those with dilated or hypertrophic cardiomyopathy. 
We defined coronary risk factors as hypertension, dyslipidemia, and diabetes 
mellitus. Hypertension was defined as a blood pressure ≥140/90 mmHg or the use of 
antihypertensive medication. Dyslipidemia was defined as elevated low-density-lipoprotein 
cholesterol (≥120 mg/dL), reduced high-density-lipoprotein cholesterol (<40 mg/dL), 
triglycerides ≥150 mg/dL, or the use of antilipidemic drugs. Diabetes mellitus was defined 
as a fasting blood sugar ≥126 mg/dL and an HbA1c ≥6.5%, or the use of insulin or oral 
antihyperglycemic drugs. 
Transthoracic echocardiography was performed to evaluate the LVEF in all 
patients before ASV therapy; LVEF was calculated by the modified Simpson’s method. 
We also took a blood sample to evaluate the BNP level before ASV therapy. BNP and 
LVEF were then re-evaluated 6 months after ASV therapy to assess the effect on 
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short-term prognosis. We also used LVEF and BNP to evaluate the severity of HF between 
patients with fatal cardiovascular event. 
Outcomes 
 The primary endpoint was fatal cardiovascular mortality at 3 years, defined as 
death from myocardial infarction, cardioembolic stroke, or fatal cardiac arrhythmias. We 
excluded patients with non-cardiac fatal events. 
Statistical analysis 
 All values are shown as mean ± standard deviation (SD) or median (25%–75% 
inter-quartile range). Normally distributed data were evaluated by Fisher’s exact test for 
binary variables or by one-way analysis of variance for continuous variables. 
Non-normally distributed data were evaluated by the χ2 test for binary variables or by the 
Kruskal–Wallis test for continuous variables. The log-rank test was used to compare the 
fatal cardiovascular event-free rate among the three groups. Repeated-measures analysis of 
variance was used to evaluate whether ASV therapy improved BNP and LVEF among the 
three AHI groups. We considered P-values <0.05 to be significant in all comparisons. All 
statistical analyses were conducted using EZR (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan). EZR is a graphical user interface for R (The R Foundation for 
Statistical Computing, Vienna, Austria) with a modified version R command designed to 
add statistical functions that are used frequently in biostatistics. 
 
Results 
Characteristics of patients 
 Table 1 shows the patient characteristics before ASV therapy. We enrolled 61 
patients in this study and classified them into three groups by the severity of SDB. No 
significant differences were apparent among the three groups with respect to age and 
 8 
 
gender, body mass index, BNP, and LVEF. The mean age was 70 ± 10 years and men 
accounted for the majority of participants (68.9%). The median BNP levels before ASV 
therapy were as follows: 379 (260–503) pg/ml in the mild group, 590 (187–560) pg/ml in 
the moderate group, and 488 (202–629) pg/ml in the severe group (P = 0.481). The mean 
LVEFs before ASV therapy were as follows: 46.2% ± 17.2% in the mild group, 43.9% ± 
17.2% in the moderate group, and 44.1% ± 17.9% in the severe group (P = 0.917). 
Sleep study 
 Table 2 shows the results of full-night polysomnography before ASV therapy. 
There were no significant differences in the total sleeping time or sleep efficacy among the 
three groups. As expected though, significant differences did exist in the arousal index, 
AHI, CSA index, and obstructive sleep index, which were positively correlated with the 
severity of SDB. 
Fatal cardiovascular event-free rate 
 Figure 1 shows the Kaplan–Meier survival curves for the fatal cardiovascular 
event-free rate among the three groups by SDB severity. After the 3-year follow up, no 
significant difference was observed in the risk of fatal cardiovascular events (log-rank test: 
P = 0.207). ASV therapy was effective for all patients, regardless of the severity of SDB. 
The differences between patients with fatal cardiovascular events and those with non-fatal 
cardiovascular events are summarized in Table 3. No significant differences were observed 
by age and gender, BNP, LVEF, or AHI between those with and without fatal 
cardiovascular events. 
Improvement of LVEF and BNP level 
 The BNP level and LVEF were improved almost equally in the three groups after 
ASV treatment (fig. 2). Although the BNP level decreased significantly in each group from 
before to after ASV therapy (changes of BNP levels: mild group, 146 [25–240] pg/ml; 
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moderate group; 286 [4.97–289] pg/ml; and severe group, 348 [82–509] pg/ml), there was 
no significant difference among the three groups (P = 0.339). Similarly, although the 
LVEF increased significantly in each group from before to after ASV therapy (changes of 
LVEF: mild group, 8.83% ± 11.9%; moderate group; 12.5% ± 12.0%; and severe group; 
8.11% ± 12.5%), there was no significant difference among the three groups (P = 0.491). 
 
Discussion 
 Findings and Data interpretation 
 In this study, we found that ASV therapy improved both the short- and long-term 
prognosis of patients with HF, regardless of the severity of SDB. 
First, ASV therapy improved the long-term prognosis for patients with HF, 
regardless of SDB severity. To our knowledge, there are no reports on this relationship 
between the effects of ASV therapy and SDB severity. Although it is well known that the 
prognosis of patients is negatively correlated with the severity of SDB [9], little has been 
reported on the long-term prognosis in patients with HF after initiating ASV therapy. 
Earlier, we showed that ASV therapy was effective for patients with HF and that it 
improved their prognosis after one year [13]. Furthermore, Yoshihisa et al. reported that 
ASV therapy improved the long-term prognosis of patients with chronic HF and CSR for 
about 3 years, and that of patients with HF, preserved LVEF, and SDB for about 4 years 
[14,15]. Similar research also suggested that ASV therapy could improve the prognosis of 
patients with HF and comorbid chronic kidney disease and SDB [16]. However, the 
present report differs from those reports [13-16] in that we evaluated the relationship 
between long-term prognosis and SDB severity. Indeed, we found improved long-term 
prognosis regardless of SDB severity in a larger cohort (n = 61) than previously reported. 
 10 
 
 Second, ASV therapy for patients with HF improved the short-term prognosis, as 
determined by improvements in LVEF and BNP, regardless of the severity of SDB. 
Previously, we reported that ASV treatment for patients with mild SDB resulted in 
comparable improvements in BNP and LVEF to those for patients with moderate and 
severe SDB [8]. Koyama et al. have also reported that ASV therapy for patients with HF 
effectively improved the short-term prognosis (again, assessed by LVEF and BNP), 
irrespective of the SDB severity [17]. Moreover, previous reports have revealed that ASV 
therapy improved both BNP and LVEF [2,3,17,18]. The results of the present study are 
therefore consistent with previous findings. 
 ASV therapy is usually used to treat CSA and CSR [2,3]. However, ASV therapy 
increasingly appears to be appropriate for the management of all patients with HF because 
it improves both the short- and long-term prognosis, regardless of the severity of SDB. 
ASV therapy is therefore an effective non-pharmacological therapy for all patients HF, 
which is particularly relevant given that patients with SDB have a poorer prognosis than 
those without SDB [1,9]. 
 
 Limitation 
 The present study has two main limitations. First, this study was observational 
rather than randomized. The cohort may be biased by being enrolled from a single center; 
however, we made efforts to reduce this bias by applying ASV therapy to consecutive 
patients. Second, our study population was small. The results will therefore need to be 
confirmed in a larger clinical trial. 
 
Conclusion 
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 In conclusion, this study clearly revealed that ASV therapy for patients with HF 
improved both the short- and long-term prognosis, regardless of the severity of SDB. Our 
results suggest that ASV therapy is associated with a good prognosis and is effective for all 
patients with HF and SDB. 
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Figure Legends 
Figure. 1 
Kaplan–Meier estimates of the fatal cardiovascular event-free rate by the severity of 
sleep-disordered breathing (SDB). SDB was classified as mild (apnea–hypopnea index 
[AHI] <20) moderate (AHI ≥20, but <40), and severe (AHI ≥40). The AHI was the mean 
number of apnea and hypopnea episodes per hour during sleep. The total sample included 
61 patients with HF. Log-rank test for differences in fatal cardiovascular events, P = 0.207. 
 
Figure. 2 
Comparison of the brain natriuretic peptide (BNP) and left ventricular ejection fraction 
(LVEF) before and after adaptive servo-ventilation (ASV) therapy among patients with 
mild (apnea–hypopnea index [AHI] <20) moderate (AHI ≥20, but <40), and severe (AHI 
≥40) sleep-disordered breathing (SDB). The AHI was the mean number of apnea and 
hypopnea episodes per hour during sleep. 





